1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. RESEARCH METHODOLOGY
1.2.1 SECONDARY RESEARCH
1.2.2 DATA ANALYSIS FRAMEWORK
1.2.3 MARKET SIZE ESTIMATION
1.2.4 FORECASTING
1.2.5 PRIMARY RESEARCH AND DATA VALIDATION
2. MARKET SNAPSHOT, 2021-2030 MILLION USD
2.1. MARKET SNAPSHOT
3. PORTER’S FIVE FORCE MODEL ANALYSIS
4. MARKET DYNAMICS
4.1. GROWTH DRIVERS
4.1.1 DRIVER 1
4.1.2 DRIVER 2
4.1.3 DRIVER 3
4.1.4 DRIVER 4
4.2. CHALLENGES
4.2.1 CHALLENGE 1
4.2.2 CHALLENGE 2
4.3. OPPORTUNITIES
4.3.1 OPPORTUNITY 1
4.3.2 OPPORTUNITY 2
5. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
5.1. OVERVIEW
5.2. PENICILLIN
5.2.1 PENICILLIN MARKET, BY REGION
5.2.1.1 NORTH AMERICA PENICILLIN MARKET, BY COUNTRY
5.2.1.2 EUROPE PENICILLIN MARKET, BY COUNTRY
5.2.1.3 ASIA-PACIFIC PENICILLIN MARKET, BY COUNTRY
5.2.1.4 REST OF WORLD PENICILLIN MARKET, BY COUNTRY
5.3. CEPHALOSPORIN
5.3.1 CEPHALOSPORIN MARKET, BY REGION
5.3.1.1 NORTH AMERICA CEPHALOSPORIN MARKET, BY COUNTRY
5.3.1.2 EUROPE CEPHALOSPORIN MARKET, BY COUNTRY
5.3.1.3 ASIA-PACIFIC CEPHALOSPORIN MARKET, BY COUNTRY
5.3.1.4 REST OF WORLD CEPHALOSPORIN MARKET, BY COUNTRY
5.4. CARBAPENEM
5.4.1 CARBAPENEM MARKET, BY REGION
5.4.1.1 NORTH AMERICA CARBAPENEM MARKET, BY COUNTRY
5.4.1.2 EUROPE CARBAPENEM MARKET, BY COUNTRY
5.4.1.3 ASIA-PACIFIC CARBAPENEM MARKET, BY COUNTRY
5.4.1.4 REST OF WORLD CARBAPENEM MARKET, BY COUNTRY
5.5. MONOBACTAM
5.5.1 MONOBACTAM MARKET, BY REGION
5.5.1.1 NORTH AMERICA MONOBACTAM MARKET, BY COUNTRY
5.5.1.2 EUROPE MONOBACTAM MARKET, BY COUNTRY
5.5.1.3 ASIA-PACIFIC MONOBACTAM MARKET, BY COUNTRY
5.5.1.4 REST OF WORLD MONOBACTAM MARKET, BY COUNTRY
5.6. COMBINATION
5.6.1 GLOBAL COMBINATION MARKET, BY DRUG CLASS
5.6.1.1 PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY REGION
5.6.1.1.1 NORTH AMERICA PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY
5.6.1.1.2 EUROPE PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY
5.6.1.1.3 ASIA-PACIFIC PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY
5.6.1.1.4 REST OF WORLD PENICILLIN/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY
5.6.1.2 CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY REGION
5.6.1.2.1 NORTH AMERICA CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY
5.6.1.2.2 EUROPE CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY
5.6.1.2.3 ASIA-PACIFIC CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY
5.6.1.2.4 REST OF WORLD CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY
5.6.1.3 CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY REGION
5.6.1.3.1 NORTH AMERICA CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY
5.6.1.3.2 EUROPE CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY
5.6.1.3.3 ASIA-PACIFIC CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY
5.6.1.3.4 REST OF WORLD CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET, BY COUNTRY
5.6.2 COMBINATION MARKET, BY REGION
5.6.2.1 NORTH AMERICA COMBINATION MARKET, BY COUNTRY
5.6.2.2 EUROPE COMBINATION MARKET, BY COUNTRY
5.6.2.3 ASIA-PACIFIC COMBINATION MARKET, BY COUNTRY
5.6.2.4 REST OF WORLD COMBINATION MARKET, BY COUNTRY
6. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
6.1. OVERVIEW
6.2. URINARY TRACT INFECTION
6.2.1 URINARY TRACT INFECTION MARKET, BY REGION
6.2.1.1 NORTH AMERICA URINARY TRACT INFECTION MARKET, BY COUNTRY
6.2.1.2 EUROPE URINARY TRACT INFECTION MARKET, BY COUNTRY
6.2.1.3 ASIA-PACIFIC URINARY TRACT INFECTION MARKET, BY COUNTRY
6.2.1.4 REST OF WORLD URINARY TRACT INFECTION MARKET, BY COUNTRY
6.3. RESPIRATORY INFECTION
6.3.1 RESPIRATORY INFECTION MARKET, BY REGION
6.3.1.1 NORTH AMERICA RESPIRATORY INFECTION MARKET, BY COUNTRY
6.3.1.2 EUROPE RESPIRATORY INFECTION MARKET, BY COUNTRY
6.3.1.3 ASIA-PACIFIC RESPIRATORY INFECTION MARKET, BY COUNTRY
6.3.1.4 REST OF WORLD RESPIRATORY INFECTION MARKET, BY COUNTRY
6.4. SKIN INFECTION
6.4.1 SKIN INFECTION MARKET, BY REGION
6.4.1.1 NORTH AMERICA SKIN INFECTION MARKET, BY COUNTRY
6.4.1.2 EUROPE SKIN INFECTION MARKET, BY COUNTRY
6.4.1.3 ASIA-PACIFIC SKIN INFECTION MARKET, BY COUNTRY
6.4.1.4 REST OF WORLD SKIN INFECTION MARKET, BY COUNTRY
6.5. COMPLICATED URINARY TRACT INFECTION
6.5.1 COMPLICATED URINARY TRACT INFECTION MARKET, BY REGION
6.5.1.1 NORTH AMERICA COMPLICATED URINARY TRACT INFECTION MARKET, BY COUNTRY
6.5.1.2 EUROPE COMPLICATED URINARY TRACT INFECTION MARKET, BY COUNTRY
6.5.1.3 ASIA-PACIFIC COMPLICATED URINARY TRACT INFECTION MARKET, BY COUNTRY
6.5.1.4 REST OF WORLD COMPLICATED URINARY TRACT INFECTION MARKET, BY COUNTRY
6.6. COMPLICATED INTRA-ABDOMINAL INFECTIONS
6.6.1 COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET, BY REGION
6.6.1.1 NORTH AMERICA COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET, BY COUNTRY
6.6.1.2 EUROPE COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET, BY COUNTRY
6.6.1.3 ASIA-PACIFIC COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET, BY COUNTRY
6.6.1.4 REST OF WORLD COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET, BY COUNTRY
6.7. NOSOCOMIAL PNEUMONIA
6.7.1 GLOBAL NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
6.7.1.1 HOSPITAL ACQUIRED PNEUMONIA MARKET, BY REGION
6.7.1.1.1 NORTH AMERICA HOSPITAL ACQUIRED PNEUMONIA MARKET, BY COUNTRY
6.7.1.1.2 EUROPE HOSPITAL ACQUIRED PNEUMONIA MARKET, BY COUNTRY
6.7.1.1.3 ASIA-PACIFIC HOSPITAL ACQUIRED PNEUMONIA MARKET, BY COUNTRY
6.7.1.1.4 REST OF WORLD HOSPITAL ACQUIRED PNEUMONIA MARKET, BY COUNTRY
6.7.1.2 VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY REGION
6.7.1.2.1 NORTH AMERICA VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY COUNTRY
6.7.1.2.2 EUROPE VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY COUNTRY
6.7.1.2.3 ASIA-PACIFIC VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY COUNTRY
6.7.1.2.4 REST OF WORLD VENTILATOR ASSOCIATED PNEUMONIA MARKET, BY COUNTRY
6.7.1.3 OTHER NOSOCOMIAL PNEUMONIA MARKET, BY REGION
6.7.1.3.1 NORTH AMERICA OTHER NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
6.7.1.3.2 EUROPE OTHER NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
6.7.1.3.3 ASIA-PACIFIC OTHER NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
6.7.1.3.4 REST OF WORLD OTHER NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
6.7.2 NOSOCOMIAL PNEUMONIA MARKET, BY REGION
6.7.2.1 NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
6.7.2.2 EUROPE NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
6.7.2.3 ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
6.7.2.4 REST OF WORLD NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
6.8. BLOOD STREAM INFECTION
6.8.1 BLOOD STREAM INFECTION MARKET, BY REGION
6.8.1.1 NORTH AMERICA BLOOD STREAM INFECTION MARKET, BY COUNTRY
6.8.1.2 EUROPE BLOOD STREAM INFECTION MARKET, BY COUNTRY
6.8.1.3 ASIA-PACIFIC BLOOD STREAM INFECTION MARKET, BY COUNTRY
6.8.1.4 REST OF WORLD BLOOD STREAM INFECTION MARKET, BY COUNTRY
6.9. OTHER DISEASES
6.9.1 OTHER DISEASES MARKET, BY REGION
6.9.1.1 NORTH AMERICA OTHER DISEASES MARKET, BY COUNTRY
6.9.1.2 EUROPE OTHER DISEASES MARKET, BY COUNTRY
6.9.1.3 ASIA-PACIFIC OTHER DISEASES MARKET, BY COUNTRY
6.9.1.4 REST OF WORLD OTHER DISEASES MARKET, BY COUNTRY
7. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
7.1. OVERVIEW
7.2. ORAL
7.2.1 ORAL MARKET, BY REGION
7.2.1.1 NORTH AMERICA ORAL MARKET, BY COUNTRY
7.2.1.2 EUROPE ORAL MARKET, BY COUNTRY
7.2.1.3 ASIA-PACIFIC ORAL MARKET, BY COUNTRY
7.2.1.4 REST OF WORLD ORAL MARKET, BY COUNTRY
7.3. INTRAVENOUS
7.3.1 INTRAVENOUS MARKET, BY REGION
7.3.1.1 NORTH AMERICA INTRAVENOUS MARKET, BY COUNTRY
7.3.1.2 EUROPE INTRAVENOUS MARKET, BY COUNTRY
7.3.1.3 ASIA-PACIFIC INTRAVENOUS MARKET, BY COUNTRY
7.3.1.4 REST OF WORLD INTRAVENOUS MARKET, BY COUNTRY
7.4. OTHER ROUTE OF ADMINISTRATION
7.4.1 OTHER ROUTE OF ADMINISTRATION MARKET, BY REGION
7.4.1.1 NORTH AMERICA OTHER ROUTE OF ADMINISTRATION MARKET, BY COUNTRY
7.4.1.2 EUROPE OTHER ROUTE OF ADMINISTRATION MARKET, BY COUNTRY
7.4.1.3 ASIA-PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET, BY COUNTRY
7.4.1.4 REST OF WORLD OTHER ROUTE OF ADMINISTRATION MARKET, BY COUNTRY
8. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY REGION
8.1. OVERVIEW
8.2. NORTH AMERICA
8.2.1 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.2.1.1 NORTH AMERICA COMBINATION MARKET, BY DRUG CLASS
8.2.2 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.2.2.1 NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.2.3 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.2.4 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS, MARKET BY COUNTRY
8.2.4.1 U.S.
8.2.4.1.1 U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.2.4.1.1.1. U.S. COMBINATION MARKET, BY DRUG CLASS
8.2.4.1.2 U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.2.4.1.2.1. U.S. NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.2.4.1.3 U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.2.4.2 CANADA
8.2.4.2.1 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.2.4.2.1.1. CANADA COMBINATION MARKET, BY DRUG CLASS
8.2.4.2.2 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.2.4.2.2.1. CANADA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.2.4.2.3 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.2.4.3 MEXICO
8.2.4.3.1 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.2.4.3.1.1. MEXICO COMBINATION MARKET, BY DRUG CLASS
8.2.4.3.2 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.2.4.3.2.1. MEXICO NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.2.4.3.3 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.3. EUROPE
8.3.1 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.3.1.1 EUROPE COMBINATION MARKET, BY DRUG CLASS
8.3.2 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.3.2.1 EUROPE NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.3.3 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.3.4 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS, MARKET BY COUNTRY
8.3.4.1 GERMANY
8.3.4.1.1 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.3.4.1.1.1. GERMANY COMBINATION MARKET, BY DRUG CLASS
8.3.4.1.2 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.3.4.1.2.1. GERMANY NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.3.4.1.3 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.3.4.2 UK
8.3.4.2.1 UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.3.4.2.1.1. UK COMBINATION MARKET, BY DRUG CLASS
8.3.4.2.2 UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.3.4.2.2.1. UK NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.3.4.2.3 UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.3.4.3 FRANCE
8.3.4.3.1 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.3.4.3.1.1. FRANCE COMBINATION MARKET, BY DRUG CLASS
8.3.4.3.2 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.3.4.3.2.1. FRANCE NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.3.4.3.3 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.3.4.4 SPAIN
8.3.4.4.1 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.3.4.4.1.1. SPAIN COMBINATION MARKET, BY DRUG CLASS
8.3.4.4.2 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.3.4.4.2.1. SPAIN NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.3.4.4.3 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.3.4.5 ITALY
8.3.4.5.1 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.3.4.5.1.1. ITALY COMBINATION MARKET, BY DRUG CLASS
8.3.4.5.2 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.3.4.5.2.1. ITALY NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.3.4.5.3 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.3.4.6 REST OF EUROPE
8.3.4.6.1 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.3.4.6.1.1. REST OF EUROPE COMBINATION MARKET, BY DRUG CLASS
8.3.4.6.2 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.3.4.6.2.1. REST OF EUROPE NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.3.4.6.3 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.4. ASIA-PACIFIC
8.4.1 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.4.1.1 ASIA-PACIFIC COMBINATION MARKET, BY DRUG CLASS
8.4.2 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.4.2.1 ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.4.3 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.4.4 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS, MARKET BY COUNTRY
8.4.4.1 JAPAN
8.4.4.1.1 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.4.4.1.1.1. JAPAN COMBINATION MARKET, BY DRUG CLASS
8.4.4.1.2 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.4.4.1.2.1. JAPAN NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.4.4.1.3 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.4.4.2 INDIA
8.4.4.2.1 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.4.4.2.1.1. INDIA COMBINATION MARKET, BY DRUG CLASS
8.4.4.2.2 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.4.4.2.2.1. INDIA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.4.4.2.3 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.4.4.3 CHINA
8.4.4.3.1 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.4.4.3.1.1. CHINA COMBINATION MARKET, BY DRUG CLASS
8.4.4.3.2 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.4.4.3.2.1. CHINA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.4.4.3.3 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.4.4.4 SOUTH KOREA
8.4.4.4.1 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.4.4.4.1.1. SOUTH KOREA COMBINATION MARKET, BY DRUG CLASS
8.4.4.4.2 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.4.4.4.2.1. SOUTH KOREA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.4.4.4.3 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.4.4.5 INDONESIA
8.4.4.5.1 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.4.4.5.1.1. INDONESIA COMBINATION MARKET, BY DRUG CLASS
8.4.4.5.2 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.4.4.5.2.1. INDONESIA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.4.4.5.3 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.4.4.6 THAILAND
8.4.4.6.1 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.4.4.6.1.1. THAILAND COMBINATION MARKET, BY DRUG CLASS
8.4.4.6.2 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.4.4.6.2.1. THAILAND NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.4.4.6.3 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.4.4.7 VIETNAM
8.4.4.7.1 VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.4.4.7.1.1. VIETNAM COMBINATION MARKET, BY DRUG CLASS
8.4.4.7.2 VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.4.4.7.2.1. VIETNAM NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.4.4.7.3 VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.4.4.8 TAIWAN
8.4.4.8.1 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.4.4.8.1.1. TAIWAN COMBINATION MARKET, BY DRUG CLASS
8.4.4.8.2 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.4.4.8.2.1. TAIWAN NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.4.4.8.3 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.4.4.9 REST OF ASIA-PACIFIC
8.4.4.9.1 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.4.4.9.1.1. REST OF ASIA-PACIFIC COMBINATION MARKET, BY DRUG CLASS
8.4.4.9.2 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.4.4.9.2.1. REST OF ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.4.4.9.3 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.5. REST OF WORLD
8.5.1 REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.5.1.1 REST OF WORLD COMBINATION MARKET, BY DRUG CLASS
8.5.2 REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.5.2.1 REST OF WORLD NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.5.3 REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.5.4 REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS, MARKET BY COUNTRY
8.5.4.1 BRAZIL
8.5.4.1.1 BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.5.4.1.1.1. BRAZIL COMBINATION MARKET, BY DRUG CLASS
8.5.4.1.2 BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.5.4.1.2.1. BRAZIL NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.5.4.1.3 BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.5.4.2 SAUDI ARABIA
8.5.4.2.1 SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.5.4.2.1.1. SAUDI ARABIA COMBINATION MARKET, BY DRUG CLASS
8.5.4.2.2 SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.5.4.2.2.1. SAUDI ARABIA NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.5.4.2.3 SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
8.5.4.3 REMAINING COUNTRIES
8.5.4.3.1 REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DRUG CLASS
8.5.4.3.1.1. REMAINING COUNTRIES COMBINATION MARKET, BY DRUG CLASS
8.5.4.3.2 REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY DISEASE
8.5.4.3.2.1. REMAINING COUNTRIES NOSOCOMIAL PNEUMONIA MARKET, BY DISEASE
8.5.4.3.3 REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
9. COMPANY PROFILES
9.1. ABBOTT LABORATORIES
9.1.1 COMPANY OVERVIEW
9.1.2 COMPANY SNAPSHOT
9.1.3 OPERATING BUSINESS SEGMENTS
9.1.4 PRODUCT PORTFOLIO
9.1.5 BUSINESS PERFORMANCE
9.1.6 KEY STRATEGIC MOVES AND DEVELOPMENT
9.2. ALLERGAN PLC.
9.2.1 COMPANY OVERVIEW
9.2.2 COMPANY SNAPSHOT
9.2.3 OPERATING BUSINESS SEGMENTS
9.2.4 PRODUCT PORTFOLIO
9.2.5 BUSINESS PERFORMANCE
9.2.6 KEY STRATEGIC MOVES AND DEVELOPMENT
9.3. F. HOFFMANN-LA ROCHE LTD.
9.3.1 COMPANY OVERVIEW
9.3.2 COMPANY SNAPSHOT
9.3.3 OPERATING BUSINESS SEGMENTS
9.3.4 PRODUCT PORTFOLIO
9.3.5 BUSINESS PERFORMANCE
9.3.6 KEY STRATEGIC MOVES AND DEVELOPMENT
9.4. GLAXOSMITHKLINE PLC
9.4.1 COMPANY OVERVIEW
9.4.2 COMPANY SNAPSHOT
9.4.3 OPERATING BUSINESS SEGMENTS
9.4.4 PRODUCT PORTFOLIO
9.4.5 BUSINESS PERFORMANCE
9.4.6 KEY STRATEGIC MOVES AND DEVELOPMENT
9.5. MERCK & CO. INC.
9.5.1 COMPANY OVERVIEW
9.5.2 COMPANY SNAPSHOT
9.5.3 OPERATING BUSINESS SEGMENTS
9.5.4 PRODUCT PORTFOLIO
9.5.5 BUSINESS PERFORMANCE
9.5.6 KEY STRATEGIC MOVES AND DEVELOPMENT
9.6. MYLAN N.V.
9.6.1 COMPANY OVERVIEW
9.6.2 COMPANY SNAPSHOT
9.6.3 OPERATING BUSINESS SEGMENTS
9.6.4 PRODUCT PORTFOLIO
9.6.5 BUSINESS PERFORMANCE
9.6.6 KEY STRATEGIC MOVES AND DEVELOPMENT
9.7. NOVARTIS INTERNATIONAL AG
9.7.1 COMPANY OVERVIEW
9.7.2 COMPANY SNAPSHOT
9.7.3 OPERATING BUSINESS SEGMENTS
9.7.4 PRODUCT PORTFOLIO
9.7.5 BUSINESS PERFORMANCE
9.7.6 KEY STRATEGIC MOVES AND DEVELOPMENT
9.8. PFIZER INC.
9.8.1 COMPANY OVERVIEW
9.8.2 COMPANY SNAPSHOT
9.8.3 OPERATING BUSINESS SEGMENTS
9.8.4 PRODUCT PORTFOLIO
9.8.5 BUSINESS PERFORMANCE
9.8.6 KEY STRATEGIC MOVES AND DEVELOPMENT
9.9. SANOFI
9.9.1 COMPANY OVERVIEW
9.9.2 COMPANY SNAPSHOT
9.9.3 OPERATING BUSINESS SEGMENTS
9.9.4 PRODUCT PORTFOLIO
9.9.5 BUSINESS PERFORMANCE
9.9.6 KEY STRATEGIC MOVES AND DEVELOPMENT
9.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
9.10.1 COMPANY OVERVIEW
9.10.2 COMPANY SNAPSHOT
9.10.3 OPERATING BUSINESS SEGMENTS
9.10.4 PRODUCT PORTFOLIO
9.10.5 BUSINESS PERFORMANCE
9.10.6 KEY STRATEGIC MOVES AND DEVELOPMENT
LIST OF TABLES
TABLE 1. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 2. PENICILLIN MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 3. NORTH AMERICA PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 4. EUROPE PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 5. ASIA-PACIFIC PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 6. REST OF WORLD PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 7. CEPHALOSPORIN MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 8. NORTH AMERICA CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 9. EUROPE CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 10. ASIA-PACIFIC CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 11. REST OF WORLD CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 12. CARBAPENEM MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 13. NORTH AMERICA CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 14. EUROPE CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 15. ASIA-PACIFIC CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 16. REST OF WORLD CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 17. MONOBACTAM MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 18. NORTH AMERICA MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 19. EUROPE MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 20. ASIA-PACIFIC MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 21. REST OF WORLD MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 22. GLOBAL COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 23. PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 24. NORTH AMERICA PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 25. EUROPE PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 26. ASIA-PACIFIC PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 27. REST OF WORLD PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 28. CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 29. NORTH AMERICA CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 30. EUROPE CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 31. ASIA-PACIFIC CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 32. REST OF WORLD CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 33. CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 34. NORTH AMERICA CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 35. EUROPE CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 36. ASIA-PACIFIC CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 37. REST OF WORLD CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 38. COMBINATION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 39. NORTH AMERICA COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 40. EUROPE COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 41. ASIA-PACIFIC COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 42. REST OF WORLD COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 43. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 44. URINARY TRACT INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 45. NORTH AMERICA URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 46. EUROPE URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 47. ASIA-PACIFIC URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 48. REST OF WORLD URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 49. RESPIRATORY INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 50. NORTH AMERICA RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 51. EUROPE RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 52. ASIA-PACIFIC RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 53. REST OF WORLD RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 54. SKIN INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 55. NORTH AMERICA SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 56. EUROPE SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 57. ASIA-PACIFIC SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 58. REST OF WORLD SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 59. COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 60. NORTH AMERICA COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 61. EUROPE COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 62. ASIA-PACIFIC COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 63. REST OF WORLD COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 64. COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 65. NORTH AMERICA COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 66. EUROPE COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 67. ASIA-PACIFIC COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 68. REST OF WORLD COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 69. GLOBAL NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 70. HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 71. NORTH AMERICA HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 72. EUROPE HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 73. ASIA-PACIFIC HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 74. REST OF WORLD HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 75. VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 76. NORTH AMERICA VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 77. EUROPE VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 78. ASIA-PACIFIC VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 79. REST OF WORLD VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 80. OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 81. NORTH AMERICA OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 82. EUROPE OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 83. ASIA-PACIFIC OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 84. REST OF WORLD OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 85. NOSOCOMIAL PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 86. NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 87. EUROPE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 88. ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 89. REST OF WORLD NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 90. BLOOD STREAM INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 91. NORTH AMERICA BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 92. EUROPE BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 93. ASIA-PACIFIC BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 94. REST OF WORLD BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 95. OTHER DISEASES MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 96. NORTH AMERICA OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 97. EUROPE OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 98. ASIA-PACIFIC OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 99. REST OF WORLD OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 100. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 101. ORAL MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 102. NORTH AMERICA ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 103. EUROPE ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 104. ASIA-PACIFIC ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 105. REST OF WORLD ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 106. INTRAVENOUS MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 107. NORTH AMERICA INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 108. EUROPE INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 109. ASIA-PACIFIC INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 110. REST OF WORLD INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 111. OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 112. NORTH AMERICA OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 113. EUROPE OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 114. ASIA-PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 115. REST OF WORLD OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
TABLE 116. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD
TABLE 117. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 118. NORTH AMERICA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 119. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 120. NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 121. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 122. U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 123. U.S. COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 124. U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 125. U.S. NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 126. U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 127. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 128. CANADA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 129. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 130. CANADA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 131. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 132. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 133. MEXICO COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 134. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 135. MEXICO NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 136. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 137. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 138. EUROPE COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 139. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 140. EUROPE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 141. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 142. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 143. GERMANY COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 144. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 145. GERMANY NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 146. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 147. UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 148. UK COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 149. UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 150. UK NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 151. UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 152. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 153. FRANCE COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 154. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 155. FRANCE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 156. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 157. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 158. SPAIN COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 159. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 160. SPAIN NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 161. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 162. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 163. ITALY COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 164. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 165. ITALY NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 166. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 167. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 168. REST OF EUROPE COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 169. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 170. REST OF EUROPE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 171. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 172. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 173. ASIA-PACIFIC COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 174. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 175. ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 176. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 177. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 178. JAPAN COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 179. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 180. JAPAN NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 181. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 182. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 183. INDIA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 184. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 185. INDIA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 186. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 187. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 188. CHINA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 189. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 190. CHINA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 191. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 192. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 193. SOUTH KOREA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 194. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 195. SOUTH KOREA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 196. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 197. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 198. INDONESIA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 199. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 200. INDONESIA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 201. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 202. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 203. THAILAND COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 204. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 205. THAILAND NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 206. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 207. VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 208. VIETNAM COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 209. VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 210. VIETNAM NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 211. VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 212. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 213. TAIWAN COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 214. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 215. TAIWAN NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 216. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 217. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 218. REST OF ASIA-PACIFIC COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 219. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 220. REST OF ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 221. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 222. REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 223. REST OF WORLD COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 224. REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 225. REST OF WORLD NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 226. REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 227. BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 228. BRAZIL COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 229. BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 230. BRAZIL NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 231. BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 232. SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 233. SAUDI ARABIA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 234. SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 235. SAUDI ARABIA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 236. SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 237. REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 238. REMAINING COUNTRIES COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
TABLE 239. REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 240. REMAINING COUNTRIES NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
TABLE 241. REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
TABLE 242. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 243. ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 244. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 245. ABBOTT LABORATORIES: KEY STRATERGY
TABLE 246. ALLERGAN PLC.: COMPANY SNAPSHOT
TABLE 247. ALLERGAN PLC.: OPERATING SEGMENTS
TABLE 248. ALLERGAN PLC.: PRODUCT PORTFOLIO
TABLE 249. ALLERGAN PLC.: KEY STRATERGY
TABLE 250. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 251. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
TABLE 252. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 253. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGY
TABLE 254. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 255. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 256. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 257. GLAXOSMITHKLINE PLC: KEY STRATERGY
TABLE 258. MERCK & CO. INC.: COMPANY SNAPSHOT
TABLE 259. MERCK & CO. INC.: OPERATING SEGMENTS
TABLE 260. MERCK & CO. INC.: PRODUCT PORTFOLIO
TABLE 261. MERCK & CO. INC.: KEY STRATERGY
TABLE 262. MYLAN N.V.: COMPANY SNAPSHOT
TABLE 263. MYLAN N.V.: OPERATING SEGMENTS
TABLE 264. MYLAN N.V.: PRODUCT PORTFOLIO
TABLE 265. MYLAN N.V.: KEY STRATERGY
TABLE 266. NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
TABLE 267. NOVARTIS INTERNATIONAL AG: OPERATING SEGMENTS
TABLE 268. NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
TABLE 269. NOVARTIS INTERNATIONAL AG: KEY STRATERGY
TABLE 270. PFIZER INC.: COMPANY SNAPSHOT
TABLE 271. PFIZER INC.: OPERATING SEGMENTS
TABLE 272. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 273. PFIZER INC.: KEY STRATERGY
TABLE 274. SANOFI: COMPANY SNAPSHOT
TABLE 275. SANOFI: OPERATING SEGMENTS
TABLE 276. SANOFI: PRODUCT PORTFOLIO
TABLE 277. SANOFI: KEY STRATERGY
TABLE 278. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 279. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 280. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 281. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGY
LIST OF FIGURES
FIGURE 1. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 2. PENICILLIN MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 3. NORTH AMERICA PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 4. EUROPE PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 5. ASIA-PACIFIC PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 6. REST OF WORLD PENICILLIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 7. CEPHALOSPORIN MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 8. NORTH AMERICA CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 9. EUROPE CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 10. ASIA-PACIFIC CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 11. REST OF WORLD CEPHALOSPORIN MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 12. CARBAPENEM MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 13. NORTH AMERICA CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 14. EUROPE CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 15. ASIA-PACIFIC CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 16. REST OF WORLD CARBAPENEM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 17. MONOBACTAM MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 18. NORTH AMERICA MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 19. EUROPE MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 20. ASIA-PACIFIC MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 21. REST OF WORLD MONOBACTAM MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 22. GLOBAL COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 23. PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 24. NORTH AMERICA PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 25. EUROPE PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 26. ASIA-PACIFIC PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 27. REST OF WORLD PENICILLIN/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 28. CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 29. NORTH AMERICA CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 30. EUROPE CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 31. ASIA-PACIFIC CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 32. REST OF WORLD CEPHALOSPORINS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 33. CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 34. NORTH AMERICA CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 35. EUROPE CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 36. ASIA-PACIFIC CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 37. REST OF WORLD CARBAPENEMS/BETA LACTAMASE INHIBITORS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 38. COMBINATION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 39. NORTH AMERICA COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 40. EUROPE COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 41. ASIA-PACIFIC COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 42. REST OF WORLD COMBINATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 43. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 44. URINARY TRACT INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 45. NORTH AMERICA URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 46. EUROPE URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 47. ASIA-PACIFIC URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 48. REST OF WORLD URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 49. RESPIRATORY INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 50. NORTH AMERICA RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 51. EUROPE RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 52. ASIA-PACIFIC RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 53. REST OF WORLD RESPIRATORY INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 54. SKIN INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 55. NORTH AMERICA SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 56. EUROPE SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 57. ASIA-PACIFIC SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 58. REST OF WORLD SKIN INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 59. COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 60. NORTH AMERICA COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 61. EUROPE COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 62. ASIA-PACIFIC COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 63. REST OF WORLD COMPLICATED URINARY TRACT INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 64. COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 65. NORTH AMERICA COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 66. EUROPE COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 67. ASIA-PACIFIC COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 68. REST OF WORLD COMPLICATED INTRA-ABDOMINAL INFECTIONS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 69. GLOBAL NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 70. HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 71. NORTH AMERICA HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 72. EUROPE HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 73. ASIA-PACIFIC HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 74. REST OF WORLD HOSPITAL ACQUIRED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 75. VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 76. NORTH AMERICA VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 77. EUROPE VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 78. ASIA-PACIFIC VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 79. REST OF WORLD VENTILATOR ASSOCIATED PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 80. OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 81. NORTH AMERICA OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 82. EUROPE OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 83. ASIA-PACIFIC OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 84. REST OF WORLD OTHER NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 85. NOSOCOMIAL PNEUMONIA MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 86. NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 87. EUROPE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 88. ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 89. REST OF WORLD NOSOCOMIAL PNEUMONIA MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 90. BLOOD STREAM INFECTION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 91. NORTH AMERICA BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 92. EUROPE BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 93. ASIA-PACIFIC BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 94. REST OF WORLD BLOOD STREAM INFECTION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 95. OTHER DISEASES MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 96. NORTH AMERICA OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 97. EUROPE OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 98. ASIA-PACIFIC OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 99. REST OF WORLD OTHER DISEASES MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 100. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 101. ORAL MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 102. NORTH AMERICA ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 103. EUROPE ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 104. ASIA-PACIFIC ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 105. REST OF WORLD ORAL MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 106. INTRAVENOUS MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 107. NORTH AMERICA INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 108. EUROPE INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 109. ASIA-PACIFIC INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 110. REST OF WORLD INTRAVENOUS MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 111. OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 112. NORTH AMERICA OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 113. EUROPE OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 114. ASIA-PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 115. REST OF WORLD OTHER ROUTE OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2021-2030, MILLION USD
FIGURE 116. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2021-2030, MILLION USD
FIGURE 117. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 118. NORTH AMERICA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 119. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 120. NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 121. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 122. U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 123. U.S. COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 124. U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 125. U.S. NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 126. U.S. BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 127. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 128. CANADA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 129. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 130. CANADA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 131. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 132. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 133. MEXICO COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 134. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 135. MEXICO NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 136. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 137. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 138. EUROPE COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 139. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 140. EUROPE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 141. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 142. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 143. GERMANY COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 144. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 145. GERMANY NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 146. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 147. UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 148. UK COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 149. UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 150. UK NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 151. UK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 152. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 153. FRANCE COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 154. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 155. FRANCE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 156. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 157. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 158. SPAIN COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 159. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 160. SPAIN NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 161. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 162. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 163. ITALY COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 164. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 165. ITALY NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 166. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 167. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 168. REST OF EUROPE COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 169. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 170. REST OF EUROPE NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 171. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 172. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 173. ASIA-PACIFIC COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 174. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 175. ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 176. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 177. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 178. JAPAN COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 179. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 180. JAPAN NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 181. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 182. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 183. INDIA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 184. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 185. INDIA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 186. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 187. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 188. CHINA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 189. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 190. CHINA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 191. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 192. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 193. SOUTH KOREA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 194. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 195. SOUTH KOREA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 196. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 197. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 198. INDONESIA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 199. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 200. INDONESIA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 201. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 202. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 203. THAILAND COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 204. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 205. THAILAND NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 206. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 207. VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 208. VIETNAM COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 209. VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 210. VIETNAM NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 211. VIETNAM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 212. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 213. TAIWAN COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 214. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 215. TAIWAN NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 216. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 217. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 218. REST OF ASIA-PACIFIC COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 219. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 220. REST OF ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 221. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 222. REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 223. REST OF WORLD COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 224. REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 225. REST OF WORLD NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 226. REST OF WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 227. BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 228. BRAZIL COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 229. BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 230. BRAZIL NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 231. BRAZIL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 232. SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 233. SAUDI ARABIA COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 234. SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 235. SAUDI ARABIA NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 236. SAUDI ARABIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 237. REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 238. REMAINING COUNTRIES COMBINATION MARKET VALUE, BY DRUG CLASS, 2021-2030, MILLION USD
FIGURE 239. REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 240. REMAINING COUNTRIES NOSOCOMIAL PNEUMONIA MARKET VALUE, BY DISEASE, 2021-2030, MILLION USD
FIGURE 241. REMAINING COUNTRIES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2030, MILLION USD
FIGURE 242. ABBOTT LABORATORIES: NET SALES,2017-2019
FIGURE 243. ALLERGAN PLC.: NET SALES,2017-2019
FIGURE 244. F. HOFFMANN-LA ROCHE LTD.: NET SALES,2017-2019
FIGURE 245. GLAXOSMITHKLINE PLC: NET SALES,2017-2019
FIGURE 246. MERCK & CO. INC.: NET SALES,2017-2019
FIGURE 247. MYLAN N.V.: NET SALES,2017-2019
FIGURE 248. NOVARTIS INTERNATIONAL AG: NET SALES,2017-2019
FIGURE 249. PFIZER INC.: NET SALES,2017-2019
FIGURE 250. SANOFI: NET SALES,2017-2019
FIGURE 251. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,2017-2019